Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT03329313

Effects of Variation of Sodium Dialysate in ICU

Led by University Hospital, Montpellier · Updated on 2025-09-30

158

Participants Needed

1

Research Sites

452 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Intermittent hemodialysis/diafiltration is a current renal replacement therapy (RRT) institued for ICU patients with AKI. For a better clinical tolerance, iinternational guidelines advise to use cold dialysate, increase duration session, decrease blood and dialysate flows, and increase level of sodium dialysate concentration (≥ 145mmol/l). Indeed, the use of a Na concentration dialysate \> 145 mmol/l improves intradialytic hemodynamic tolerance but it may also induce fluid overload by the transfert of sodium from the dialysate compartment to the blood. Yet, fluid overload has been strongly associated with mortality in critically ills. The investigators hypothesized that the use of a level in sodium dialysate at 140 mmol/l with slow low efficiency daily dialysis-filtration (SLEDD-f) will permit a fair intradialytic hemodynamic tolerance without the adverse effect of intradiaclytic Na loading from the dialysate. Two randomized groups of ICU AKI patients treated by SLEDD-f will be compared in terms of intradialytic hemodynamic tolerance and overload accordong to 140 or 145 mmol/l of Na in the dialysate

CONDITIONS

Official Title

Effects of Variation of Sodium Dialysate in ICU

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age > 18 years old
  • Acute kidney injury requiring renal replacement therapy
  • Dialysis type: on line sustained low efficiency dialy dialysis-filtration
  • SOFA score > 5
  • Sodium serum level between 135 and 145 mmol/l
Not Eligible

You will not qualify if you...

  • Chronic kidney disease stage IV or V
  • Obstructive acute kidney injury
  • Renal transplantation in the year before ICU admission
  • Moribund with risk of death in the next 48 hours
  • Vulnerable or protected persons
  • Pregnant or breastfeeding mother

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Uhmontpellier

Montpellier, Montpellier, France, 34295

Actively Recruiting

Loading map...

Research Team

V

vincent BRUNOT, MD

CONTACT

K

kada KLOUCHE, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here